HONG KONG – A leading Indian biosimilars maker reported a slight decline in biopharma sales in the quarter ending June 30, affected by the chaotic situation in the Middle East.
NEW DELHI – The first budget of India's newly elected government included some nice surprises for India's biotechnology sector in the form of international collab-orations and a new bioclusters initiative.
HONG KONG – A multidisciplinary research team from Singapore has made a significant breakthrough in the understanding of the molecular basis of benign fibroadenomas, one of the most common breast tumors in women, which could have important implications for the diagnosis and treatment of malignant breast cancers.
TOKYO – Two Japanese pharma companies are investing tens of millions into a new biotech venture fund created by Remiges Biopharma Fund LP as they look for new collaborations outside Japan.
TOKYO – A hepatitis C drug in the market in Japan since 2011 has been associated with 15 deaths in a little more than two years and with severe side effects in more than 2,500 patients, according to reports that surfaced over the weekend.
HONG KONG – Leading Chinese vaccine maker Sinovac Biotech Ltd. (NASDAQ:SVA) has emerged as the sole supplier of hepatitis A vaccine in prefilled syringe dosages for the city of Beijing.
Retrophin Inc., of New York, said it submitted a proposal to the board of Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, to acquire by scheme of arrangement all of the shares of Clinuvel stock that Retrophin does not own for 0.175 Retrophin shares per Clinuvel share, or A$2.17 (US$2.04) per share in cash.
SHANGHAI – Canbridge Life Sciences Inc., of Beijing, is on its way to bridging the gap that leaves many patients in China waiting anywhere from four years to six years for critical treatments approved in developed markets. With time of the essence, the firm is taking a portfolio approach to its in-licensing strategy, developing both clinical-stage and approved treatments, while mixing new drugs with treatments classified as medical devices.
SHANGHAI – Merck KGaA, of Darmstadt, Germany, has reiterated its commitment to China, forging ahead with its €80 million (US$107.3 million) manufacturing plant, expected to be Merck's second largest globally and its first such pharmaceutical investment in China.
Sinovac Biotech Ltd., of Beijing, said it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage to the expanded program of immunization (EPI) for Beijing. The vaccines will be used for the period from 2014 to 2016, and the company expects to begin delivery in the coming months upon demand.
RSS